# Doxorubicin Hydrochloride Liposome in Treating Women With Ductal Carcinoma in Situ Undergoing Surgery

> **NCT00671476** · NA · UNKNOWN · sponsor: **Dr. Susan Love Research Foundation** · enrollment: 30 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** pegylated liposomal doxorubicin hydrochloride
- **GENETIC:** DNA methylation analysis
- **GENETIC:** TdT-mediated dUTP nick end labeling assay
- **GENETIC:** fluorescence in situ hybridization
- **GENETIC:** loss of heterozygosity analysis
- **GENETIC:** polymerase chain reaction
- **OTHER:** immunoenzyme technique
- **OTHER:** immunohistochemistry staining method
- **OTHER:** laboratory biomarker analysis
- **PROCEDURE:** breast duct lavage
- **PROCEDURE:** neoadjuvant therapy
- **PROCEDURE:** therapeutic conventional surgery

## Key facts

- **NCT ID:** NCT00671476
- **Lead sponsor:** Dr. Susan Love Research Foundation
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-02
- **Primary completion:** 2011-02
- **Final completion:** —
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2014-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00671476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00671476, "Doxorubicin Hydrochloride Liposome in Treating Women With Ductal Carcinoma in Situ Undergoing Surgery". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00671476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*